Prosecutors in the Philippines have found probable cause to indict six Sanofi officials for its Dengvaxia rollout.

The FDA has issued guidance on continuous manufacturing and is allocating $58 million to move forward advanced manufacturing processes.

CureVac is working on a printer to quickly create mRNA vaccine candidates against known pathogens and unknown diseases.

The power struggle at Sinovac has taken another unusual turn with the company's move to implement a "poison pill" defense.

The company aims to enter the clinic with a pan-flavivirus vaccine against Zika, dengue and yellow fever in 2019.

Here is some other vaccine news of note for the week.

Sanofi has faced more than a year of controversy for its dengue vaccine, and now Philippine officials have revoked Dengvaxia's regulatory approval.

After the buy, Bharat Biotech will be able to make 25 million doses of rabies vaccine each year, its chairman said.